Human protein tyrosine phosphatase inhibitors and methods of use

A method for controlling an angiogenesis regulated disease or disorder comprising, contacting a subject with an effective amount of a compound having the formula:

• wherein R is a substituted or unsubstituted thiazolyl unit having the formula:
• R4 and R5 are each independently chosen from:
• i) hydrogen;
• ii) substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl;
• iii) substituted or unsubstituted phenyl;
• iv) substituted or unsubstituted heteroaryl;
• or
• R4 and R5 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms;
• said substitutions are independently chosen from one or more C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, halogen, hydroxyl, or cyano units;
• R6 is a unit chosen from:
• i) hydrogen;
• ii) substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl;
• iii) substituted or unsubstituted phenyl;
• and
• iv) substituted or unsubstituted heteroaryl;
• R1 is chosen from:
• i) hydrogen;
• ii) C1-C6 linear or C3-C6 branched alkyl;
• iii) substituted or unsubstituted phenyl;
• or
• iv) substituted or unsubstituted benzyl;
• R2 is chosen from:
• i) C1-C6 linear or C3-C6 branched alkyl;
• or
• ii) C1-C6 linear or C3-C6 branched alkoxy;
• R3 is hydrogen or C1-C4 linear or C3-C4 branched alkyl;
• or
• a pharmaceutically acceptable salt thereof;
• wherein the angiogenesis regulated disease or disorder is chosen from skeletal muscle and myocardial ischemia, stroke, coronary artery disease, or peripheral vascular disease.